Making us thinner will see fatter profits for pharma as Bloomberg’s
crystal ball predicts obesity drug sales hitting $44B by 2030
That would be a major ballooning of a market that was worth just $2.5 billion in 2022. Bloomberg
predicts that nearly 70% of sales will stem from the U.S., with a slower ramp-up in Europe,
Read the article on Fierce Pharma >
Read More from the Global Wellness News ™